Information Provided By: 
Fly News Breaks for May 18, 2015
CLVS
May 18, 2015 | 07:27 EDT
Stifel says that rociletinib's differentiated safety/tolerability profile and apparent activity in both T790M-positive and -negative tumors, which the firm has begun including in its model, should allow the drug to be approved in early 2016. The firm thinks the company is "a compelling acquisition candidate." It keeps a Buy rating on the shares.
News For CLVS From the Last 2 Days
There are no results for your query CLVS
